To estimate the therapeutic effect of mEVs-SKAP2 on male infertility, we carried on mEVs-SKAP2 trial on human semen samples derived from three groups: normal population, individuals harboring HNRNPR mutations and patients diagnosed with idiopathic asthenoteratozoospermia (Fig. 9a). The gene discussed is SKAP2; the disease is male infertility.